Table 3.
FDA-approved/ under clinical trials vaccines for COVID-19.
| Sr. No | Vaccine Name | Type | Sponsors and Collaborators | Previous work | Phase of Development | References |
|---|---|---|---|---|---|---|
| 1. | BNT162 | Vaccine | Pfizer Inc. &BioNTech SE | – | Approved | [250] |
| 2. | mRNA-1273 | Vaccine | Moderna | – | Approved | [251] |
| 3. | Sputnik V | Muscle Injection | Gamaleya Research Institute | Approved | [252] | |
| 2. | No name yet | Oral recombinant Vaccine | Vaxart Inc. VXRT, + 2.35% | – | Phase III clinical trials | [253], [254] |
| 3. | No name yet | Recombinant vaccines. | Sanofi SNY,& BARDA | – | Preclinical | [255] |
| 4. | No name yet | Matrix-M™ adjuvant with COVID-19 vaccine to enhance immune responses. | Novavax Inc. NVAX, | Ebola vaccine, NanoFlu™, ResVax™, | Phase I clinical trials | [256] |
| 5. | AS03 Adjuvant System | A pandemic adjuvant platform for vaccines | GlaxoSmithKline (GSK), and CEPI | brought to market vaccines for human papillomavirus (HPV) and the seasonal flu. | Preclinical studies | [257] |
| 6. | TBD vaccine is under development, so there is no specific name at this time,” | Vaccine | Johnson & Johnson JNJ, and BARDA | – | Phase 1 clinical trial | [258] |
| 7. | vaccine for the novel coronavirus | Vaccine | Heat Biologics Inc. HTBX, | – | Preclinical | [259] |
| 8. | INO-4800 | Type: DNA-based vaccine | Inovio Pharmaceuticals Inc. INO | – | Preclinical | [260] |
| 9. | mRNA-1273 | RNA-based vaccine | Biotechnology company Moderna, Inc. | – | Phase III clinical trial | [261], [262] |
| 10. | gp96 vaccine | Vaccination | Heat Biologics & University of Miami | – | Early development | [263] |
| 11. | BX-25 | Vaccination | BIOXYTRAN | – | Pre-clinical trial | [264] |
| 12. | S-Trimer vaccine | Vaccination | Clover & Dynavax | – | Pre-clinical trials | [265] |
| 13. | TNX-1800 | Vaccination | Tonix Pharmaceuticals | – | Initial evaluation | [266] |
| 14. | No name yet | Infectious Bronchitis Virus (IBV) vaccine | MIGAL and IIBR | – | Pre-clinical trials | [267] |
| 15. | Pitt-Co-Vacc | Vaccination uses lab-made pieces of viral protein to build immunity in the same way as a flu. | Pittsburgh School of Medicine | – | Animal studies | [204] |
| 16. | Covaxin | Derived from a strain of the novel coronavirus | Bharat Biotech, India Institute of Medical Sciences in Patna, and Post-Graduate Institute of Medical Sciences in Rohtak | – | Phase I/II clinical trials | [268] |
| 17. | AZD1222 | Vaccine | The University of Oxford, Vaccitech, Astra Zeneca (UK-based global biopharmaceutical company) | – | Approved | [269], [270]. |